China’s Supreme People’s Court upheld a sales injunction on Infineon Technologies’ Gallium Nitride (GaN) products. The ruling concludes a significant patent dispute with Innoscience within the mainland Chinese market.
Investors and analysts are reassessing the company’s valuation and growth prospects for its GaN segment. The court’s decision introduces new risks to future revenue streams from affected products in China.
Infineon’s stock has maintained strong momentum prior to this development. The company’s shares delivered significant returns over the past year despite the ongoing legal challenges.